Robert DeLuca joined OREXO US as President in May, 2013. During his nine-year tenure he has led the U.S. company from its inception and is responsible for commercializing Orexo’s first product, Zubsolv, in the opioid use disorder treatment category. He has more than 30 years of industry experience at several multinational pharmaceutical companies and brings to OREXO a demonstrated track record of success in the pharmaceutical industry. He has extensive executive leadership experience with a combined background in global commercial operations, marketing, market access and sales. Additionally, he is considered a commercial leader especially in the Market Access and Value-based disciplines. He has progressed through senior roles of increasing responsibility at Schering Plough, Berlex, Pharmacia and Sanofi. Robert is a New Jersey licensed pharmacist and graduated from St. John’s University in New York City. He practiced retail pharmacy for three years post licensure prior to entering the corporate arena. DeLuca is a co-chair of the PheoPara Coalition Gala for the past 10 years and also has memberships in the Academy of Managed Care Pharmacy (AMCP) and the American Pharmacists Association.
